Release Date: 05/12/26
Expiration Date: 05/12/27
Program Code: 26-HF-29W
TARGET AUDIENCE: Healthcare professionals, including physicians, advanced practice providers, nurses and pharmacists who treat patients with substance use disorders.
LEARNING OBJECTIVES
Describe medication management of patients transitioning from inpatient settings who require tapering of medications used to treat medetomidine withdrawal.
Identify the clinical factors and considerations in managing medetomidine withdrawal in outpatient settings.
ACCREDITATION STATEMENT:
In support of improving patient care, this activity has been planned and implemented by American Academy of CME, Inc. and MidAtlantic AIDS Education and Training Center of the Health Federation of Philadelphia American Academy of CME, Inc. is Jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physicians: American Academy of CME, Inc., designates this Enduring Material for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurse Practitioners and Nurses: American Academy of CME, Inc., designates this educational activity for 1.5 ANCC contact hours.
Pharmacy: American Academy of CME, Inc., designates this educational activity for 1.5 ACPE contact hours. UAN: JA4008191-9999-26-040-H01-P Knowledge
Other HCPs: Other members of the care team will receive a certificate of participation on request.
DISCLOSURES
According to the disclosure policy of the Academy, all faculty, planning committee members, editors, managers and other individuals who are in a position to control content are required to disclose any relationships with any ineligible company(ies). The existence of these relationships is not viewed as implying bias or decreasing the value of the activity. Clinical content has been reviewed for fair balance and scientific objectivity, and any relevant financial relationships listed for these individuals have been mitigated.
Faculty
Kristina Walker; Judy Chertok, MD, FAACP; Rachel Truchil, MD, MPH; Keriann Shalvoy, MD, MPH, PMH-C; Kara Cohen, CRNP, CWS: No relevant financial relationships with ineligible companies to disclose.
Planning Committee
Catherine Abrams, MPH, Tanya Uritsky, PharmD, BCPP, FPPCP, John JD Juchniewicz, MCIS, CHCP, FACEHP, and Colin Bowers, MPP: No relevant financial relationships with ineligible companies to disclose.
Daniel Teixeira da Silva, MD, MSHP, discloses he is a shareholder of Atai life sciences.
This activity will not review off-label or investigational information.
FUNDING ACKNOWLEDGMENT: This project was supported by a grant from the Center for Disease Control via Philadelphia Department of Public Health, No. 1 NH28CE003536-01-00
